A combination of dabrafenib with trametinib was approved by the FDA for treatment of pediatric patients 1 year and older with low-grade glioma & BRAF V600E mutation who require systemic therapy.
Chris Ryan
Advertisement
Articles by Chris Ryan
Advertisement
Latest Updated Articles
FDA Approves Drug Combo for Young Glioma PatientsPublished: March 17th 2023 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
3
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
4
The Rise in Supplement Use Calls for Pharmacist-Led Counseling, Education | NCPA 2025
5
